MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.

Leuk Lymphoma 2018 04 22;59(4):844-854. Epub 2017 Aug 22.

b Faculty of Medicine, Cairo University , Cairo , Egypt.

JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). Among 93 patients; median MPN10 score was 48 (5-76) in JAK2 mutants versus 25 (4-80) in JAK2 negative (p < .001); 22.5 (4-65) in CALR mutants versus 35 (5-80) in CALR negative (p < .050) and 21 (10-48) in triple negative versus 40 (4-80) in JAK2/CALR/MPL mutants (p < .001). At three years, progression free and overall survival of JAK2-positive versus JAK2-negative patients were 62% versus 100% (p < .001); 85% versus 100% (p = .011) and were 100% versus 78% (p = .067); 100% versus 92% (p = .197) in CALR-positive versus CALR-negative patients and 100% versus 75% (p = .004); 100% versus 90% (p = .015) in triple negative versus mutant patients, respectively. MPN10 score in association with driver gene mutations can be used as a predictor of survival in MPN patients.

Download full-text PDF

Publisher Site Listing
April 2018

Publication Analysis

Top Keywords

mpn10 score
direct impact
5-76 jak2
symptom severity
status direct
impact symptom
jak2 mutants
mutants versus
mpns patients
mutational status
score 5-76
severity disease
patients median
myeloproliferative neoplasms
neoplasms mpns
score myeloproliferative
assessed mpn10
disease burden
median mpn10
burden assessed

Similar Publications

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.

Am J Clin Pathol 2015 May;143(5):635-44

From the Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

Objectives: We investigated mutation profiles of CALR, JAK2, and MPL in 199 Korean patients with myeloproliferative neoplasms (MPNs).

Methods: In total, 199 patients with MPN (54 primary myelofibrosis [PMF], 79 essential thrombocythemia [ET], 58 polycythemia vera [PV], and eight MPN-unclassifiable [MPN-U]) and 4 patients with acute panmyelosis with myelofibrosis (APMF) were retrospectively subjected to Sanger sequencing for CALR, JAK2, and MPL.

Results: The overall frequency of CALR mutations was 12. Read More

View Article and Full-Text PDF
May 2015

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Blood 2014 Oct 18;124(16):2507-13; quiz 2615. Epub 2014 Jul 18.

Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We examined the effect of these mutations on long-term disease outcome. Read More

View Article and Full-Text PDF
October 2014

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.

Indian J Pathol Microbiol 2018 Apr-Jun;61(2):209-213

Tata Memorial Centre, Hematopathology Laboratory, Mumbai, Maharashtra, India.

Introduction: Over the past decade, we have moved on from a predominantly morphological and clinical classification of myeloproliferative neoplasms (MPN) to a more evolved classification that accounts for the molecular heterogeneity that is unique to this subgroup of hematological malignancies. This usually incorporates mutations in Janus kinase 2 (JAK2), MPL, and calreticulin (CALR) genes. In this manuscript, we report the frequency of these mutations in a cohort of Indian patients at a tertiary cancer center. Read More

View Article and Full-Text PDF
October 2018

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Blood 2017 02 27;129(6):680-692. Epub 2016 Dec 27.

Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and.

Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 revision of the includes new criteria for the diagnosis of these disorders. Somatic mutations in the 3 driver genes, that is, , , and , represent major diagnostic criteria in combination with hematologic and morphological abnormalities. Read More

View Article and Full-Text PDF
February 2017